MedTrace Logo

Trial to Reduce Alloimmunization to Platelets (TRAP)

NCT00000589 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-11-07

No results posted yet for this study

Summary

To determine the best, clinically useful procedure to prevent or minimize platelet alloimmunization as a cause of refractoriness to platelet transfusion in patients undergoing marrow ablative chemotherapy for acute myelogenous leukemia.

Conditions

Interventions

PROCEDURE

platelet transfusion

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Hayden Braine · Johns Hopkins University

  • Kuo-Jang Kao · University of Florida

  • Jeffrey McCullough · University of Minnesota

  • Janice McFarland · Blood Center of Southeastern Wisconsin

  • Charles Schiffer · University of Maryland

  • Sherrill Schlichter · Bloodworks

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1989-08-31
Completion
1997-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000589 on ClinicalTrials.gov